Taysha Gene Therapies, Inc. Entered into A Lease Agreement with Pegasus Park, Llc
January 15, 2021 at 04:34 pm EST
Share
On January 11, 2021, Taysha Gene Therapies, Inc. (the Company) entered into a lease agreement (the Lease) with Pegasus Park, LLC, a Delaware limited liability company (the Landlord), pursuant to which the Company will lease approximately 15,000 square feet of office space at 3000 Pegasus Park Drive, Dallas, Texas 75247. The Lease commences on the date on which certain improvements to the Office Space have been made and the Office Space is tendered to the Company for possession, which the Company and the Landlord presently anticipate to be delivered on or about April 15, 2021, and will have a term of approximately ten years. The Company has an option to extend the term of the Lease for one additional period of five years. The Company's obligation for the payment of base rent for the Office Space will initially be approximately $32,500.00 per month and will increase annually, up to an estimated monthly base rent of $50,418.17 during the term of the Lease. The Company is obligated to pay operating costs and utilities applicable to the Office Space. The Company was required to provide a security deposit of $32,500.00 in connection with its entry into the Lease. The Company will be responsible for costs of constructing interior improvements within the Office Space that exceed a construction allowance provided by the Landlord not to exceed $40.00 per rentable square foot.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Companyâs lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). It received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN.
TAYSHA GENE THERAPIES, INC. 
